BioCentury | Oct 22, 2015
Distillery Therapeutics

Therapeutics: Penicillin binding protein 2a (PBP2a)

Infectious disease INDICATION: Staphylococcus In vitro and mouse studies suggest combining three β-lactam antibiotics that allosterically bind PBP2a could help treat methicillin-resistant Staphylococcus aureus (MRSA) infection. In cultures of the MRSA N315 strain, a combination...
BioCentury | May 19, 2014
Clinical News

Ceftaroline fosamil: Development discontinued

Dainippon Sumitomo disclosed in its earnings for the fiscal year ended March 31 that it discontinued development of DSP-5990, which was in Phase I testing to treat MRSA infection. The company said the antibiotic did...
BioCentury | Oct 24, 2013
Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Crystal structures of Staphylococcus aureus penicillin binding protein 2a (PBP2a) In vitro studies identified an allosteric site on PBP2a that could...
BioCentury | Jun 18, 2012
Company News

Basilea, GlaxoSmithKline sales and marketing update

Basilea granted GlaxoSmithKline's Stiefel Laboratories Inc. subsidiary exclusive, worldwide rights to the Swiss company's only marketed drug, eczema therapy Toctino alitretinoin. Basilea will receive L146 million ($226.3 million) up front and is eligible for L30-L50...
BioCentury | Apr 5, 2012
Cover Story

MRSA sensitivity training

Researchers at Merck & Co. Inc. have identified targets in methicillin-resistant Staphylococcus aureus that synergize with b-lactam antibiotic targets to restore antibiotic sensitivity. 1 The findings suggest it may now be possible to use combinations...
BioCentury | Jan 16, 2012
Clinical News

Doribax: Phase III halted

Johnson & Johnson said in a Dear Healthcare Professional letter that it terminated a double-blind, international Phase III trial after an interim analysis showed a numerically higher mortality and a numerically poorer clinical cure rate...
BioCentury | Nov 14, 2011

Inching toward feasibility

Clinical work on compounds to treat community-acquired bacterial pneumonia and hospital-acquired or ventilator-associated bacterial pneumonia has been in limbo since 2008 when FDA began reassessing its requirements for clinical trial designs, which many companies said...
BioCentury | Oct 25, 2010
Clinical News

Cayston aztreonam lysine: Additional Phase III data

Additional data from the open-label, U.S. and European Phase III Study 205-0110 trial in 268 patients showed that Cayston met the co-primary endpoint of superiority to inhaled tobramycin in mean change in percent predicted FEV1...
BioCentury | Sep 16, 2010
Targets & Mechanisms

Aggregation party in ALS

Aggregation and mislocalization of TDP-43 are at the heart of amyotrophic lateral sclerosis, but it is difficult to manipulate the protein directly because of its broad role in cellular survival. University of Pennsylvania researchers now...
BioCentury | Sep 13, 2010

Complicated but uncontroversial

Last week's FDA panel meeting to discuss ceftaroline from Forest Laboratories Inc. was devoid of the controversy that has surrounded reviews of other antibiotics to treat either community-acquired bacterial pneumonia or complicated skin and skin...
Items per page:
1 - 10 of 156